Pharmion year end results out this AM show year over year sales growth by Vidaza of less than 1 mil in the US. All the growth ex US. This performance despite the fact the survival data had been out there for 5 months of 2007. This tells me Dacogen has a very strong position in the minds of MD's and makes me feel that stock price will someday find the reality of the market. I'll wait if necessary. But this is another demonstration that we have a winner here.
BOULDER, Colo., Feb. 19 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM - News) today reported financial results for its quarter and year ended December 31, 2007. For the year, net sales totaled $267.3 million, compared to net sales of $238.6 million in 2006. Worldwide sales of Vidaza® (azacitidine for injection) totaled $165.3 million for 2007, compared to $142.2 million for 2006. In the U.S., sales of Vidaza totaled $131.4 million in 2007, compared to $130.6 million in 2006. Named patient and compassionate use sales of Vidaza in Europe and other international markets totaled $33.9 million in 2007, compared to $11.6 million in 2006. Named patient and compassionate use sales of thalidomide totaled $81.7 million in 2007, compared to $77.5 million in 2006. Fourth quarter net sales totaled $71.5 million, compared to $60.1 million in the fourth quarter of 2006. Worldwide sales of Vidaza totaled $44.8 million in the fourth quarter, compared to $36.6 million in the same quarter of 2006. In the U.S., sales of Vidaza totaled $34.2 million in the fourth quarter of 2007, compared to $32.0 million in the same period in 2006. Named patient and compassionate use sales of Vidaza in Europe and other international markets totaled $10.6 million in the fourth quarter of 2007, compared to $4.6 million in the same period in 2006. Fourth quarter named patient and compassionate use sales of thalidomide totaled $21.0 million, compared to $18.8 million in the fourth quarter of 2006.
"We are very pleased with our financial results for 2007, and very proud of the major milestones we accomplished during the year," said Patrick J. Mahaffy, Pharmion's president and CEO. "We were very excited about the results of the Vidaza overall survival study announced in August, the increasing uptake of Vidaza for European named patient and compassionate use that fueled Vidaza sales growth during the year, as well as significant progress in clinical research across our product portfolio, including the initiation of clinical studies for Amrubicin, MGCD0103 and oral Azacitidine."
I find it interesting that PHRM didn't have a webcast of their 4Q update. I guess they probably do not want many thinking about the small growth and asking some questions on what's happening out there. They do not want to do anything to rock the boat. Now the real test maybe in the Jan or Feb IMS figures. December was still a little early to see md's putting newer patients on Vidaza, instead of Dacogen, because of survival data. But, if PHRM was seeing anything positive on this fromnt, they would be webcasting the 4Q numbers and bragging on seeing any market share gain. There silence hear may be very important validation that Dacogen is holding up well. I just think PHRM doesn't want to answer the questions that this 4Q number could indicate. JMO